Glycogen synthase kinase-3β inhibition depletes the population of prostate cancer stem/progenitor-like cells and attenuates metastatic growth

Oncotarget

Volumn 5, Issue 19, 2014, Pages 8986-8994

  Kroon, Jan ^a   in't Veld, Lars S ^a   Buijs, Jeroen T ^a   Cheung, Henry ^a   van der Horst, Geertje ^a   van der Pluijm, Gabri ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Cancer stem cells; GSK 3 ; Metastasis; Prostate cancer; Wnt signaling

Indexed keywords

GLYCOGEN SYNTHASE KINASE 3BETA; VERY LATE ACTIVATION ANTIGEN 2; WNT PROTEIN; ACTIN; GLYCOGEN SYNTHASE KINASE 3; GLYCOGEN SYNTHASE KINASE 3 BETA; PROTEIN KINASE INHIBITOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER MORPHOLOGY; CANCER SIZE; CANCER STEM CELL; CARCINOGENICITY; CELL POPULATION; CLONOGENESIS; CONTROLLED STUDY; DOWN REGULATION; ENZYME ACTIVITY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; MALIGNANT TRANSFORMATION; METASTASIS; METASTASIS POTENTIAL; MOUSE; NONHUMAN; PROSTATE CANCER; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN POLYMERIZATION; TUMOR INVASION; ANIMAL; ANTAGONISTS AND INHIBITORS; BAGG ALBINO MOUSE; BIOSYNTHESIS; CELL MOTION; CELL PROLIFERATION; CYTOLOGY; DRUG EFFECTS; METABOLISM; NUDE MOUSE; PATHOLOGY; PROSTATIC NEOPLASMS; PROTEIN MULTIMERIZATION; TUMOR CELL LINE; WNT SIGNALING PATHWAY;

ACTINS; ANIMALS; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; GLYCOGEN SYNTHASE KINASE 3; HUMANS; INTEGRIN ALPHA2BETA1; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; NEOPLASM METASTASIS; NEOPLASTIC STEM CELLS; PROSTATIC NEOPLASMS; PROTEIN KINASE INHIBITORS; PROTEIN MULTIMERIZATION; WNT PROTEINS; WNT SIGNALING PATHWAY;

EID: 84907994541     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.1510     Document Type: Article

References (50)

1. Jemal A, Center MM, DeSantis C and Ward EM. Global patterns of cancer incidence and mortality rates and trends. Cancer Epidemiol Biomarkers Prev. 2010; 19(8):1893-1907.
2. Wirth MP, See WA, McLeod DG, Iversen P, Morris T, Carroll K and Casodex Early Prostate Cancer Trialists G. Bicalutamide 150 mg in addition to standard care in patients with localized or locally advanced prostate cancer: results from the second analysis of the early prostate cancer program at median followup of 5.4 years. J Urol. 2004; 172(5 Pt 1):1865-1870.
3. Petrylak DP, Tangen CM, Hussain MH, Lara PN, Jr., Jones JA, Taplin ME, Burch PA, Berry D, Moinpour C, Kohli M, Benson MC, Small EJ, Raghavan D and Crawford ED. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med. 2004; 351(15):1513-1520.
4. Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, Oudard S, Theodore C, James ND, Turesson I, Rosenthal MA, Eisenberger MA and Investigators TAX. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004; 351(15):1502-1512.
5. Attard G, Reid AH, Yap TA, Raynaud F, Dowsett M, Settatree S, Barrett M, Parker C, Martins V, Folkerd E, Clark J, Cooper CS, Kaye SB, Dearnaley D, Lee G and de Bono JS. Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven. J Clin Oncol. 2008; 26(28):4563-4571.
6. Dean M, Fojo T and Bates S. Tumour stem cells and drug resistance. Nat Rev Cancer. 2005; 5(4):275-284.
7. Wang X, Kruithof-de Julio M, Economides KD, Walker D, Yu H, Halili MV, Hu YP, Price SM, Abate-Shen C and Shen MM. A luminal epithelial stem cell that is a cell of origin for prostate cancer. Nature. 2009; 461(7263):495-500.
8. Germann M, Wetterwald A, Guzman-Ramirez N, van der Pluijm G, Culig Z, Cecchini MG, Williams ED and Thalmann GN. Stem-like cells with luminal progenitor phenotype survive castration in human prostate cancer. Stem Cells. 2012; 30(6):1076-1086.
9. Collins AT, Berry PA, Hyde C, Stower MJ and Maitland NJ. Prospective identification of tumorigenic prostate cancer stem cells. Cancer research. 2005; 65(23):10946-10951.
10. van den Hoogen C, van der Horst G, Cheung H, Buijs JT, Lippitt JM, Guzman-Ramirez N, Hamdy FC, Eaton CL, Thalmann GN, Cecchini MG, Pelger RC and van der Pluijm G. High aldehyde dehydrogenase activity identifies tumor-initiating and metastasis-initiating cells in human prostate cancer. Cancer research. 2010; 70(12):5163-5173.
11. Rayasam GV, Tulasi VK, Sodhi R, Davis JA and Ray A. Glycogen synthase kinase 3: more than a namesake. Br J Pharmacol. 2009; 156(6):885-898.
12. Jope RS and Johnson GV. The glamour and gloom of glycogen synthase kinase-3. Trends Biochem Sci. 2004; 29(2):95-102.
13. Reya T and Clevers H. Wnt signalling in stem cells and cancer. Nature. 2005; 434(7035):843-850.
14. Clevers H. Wnt/beta-catenin signaling in development and disease. Cell. 2006; 127(3):469-480.
15. Li H, Chen X, Calhoun-Davis T, Claypool K and Tang DG. PC3 human prostate carcinoma cell holoclones contain self-renewing tumor-initiating cells. Cancer research. 2008; 68(6):1820-1825.
16. van den Hoogen C, van der Horst G, Cheung H, Buijs JT, Pelger RC and van der Pluijm G. The aldehyde dehydrogenase enzyme 7A1 is functionally involved in prostate cancer bone metastasis. Clin Exp Metastasis. 2011; 28(7):615-625.
17. Engler TA, Henry JR, Malhotra S, Cunningham B, Furness K, Brozinick J, Burkholder TP, Clay MP, Clayton J, Diefenbacher C, Hawkins E, Iversen PW, Li Y, Lindstrom TD, Marquart AL, McLean J, et al. Substituted 3-imidazo[1,2-a]pyridin-3-yl-4-(1,2,3,4-tetrahydro-[1,4]diazepino-[6,7,1-hi]indol-7-yl)pyrrole-2,5-diones as highly selective and potent inhibitors of glycogen synthase kinase-3. J Med Chem. 2004; 47(16):3934-3937.
18. Miclea RL, Siebelt M, Finos L, Goeman JJ, Lowik CW, Oostdijk W, Weinans H, Wit JM, Robanus-Maandag EC and Karperien M. Inhibition of Gsk3beta in cartilage induces osteoarthritic features through activation of the canonical Wnt signaling pathway. Osteoarthritis Cartilage. 2011; 19(11):1363-1372.
19. van Bezooijen RL, Svensson JP, Eefting D, Visser A, van der Horst G, Karperien M, Quax PH, Vrieling H, Papapoulos SE, ten Dijke P and Lowik CW. Wnt but not BMP signaling is involved in the inhibitory action of sclerostin on BMP-stimulated bone formation. J Bone Miner Res. 2007; 22(1):19-28.
20. Maretto S, Cordenonsi M, Dupont S, Braghetta P, Broccoli V, Hassan AB, Volpin D, Bressan GM and Piccolo S. Mapping Wnt/beta-catenin signaling during mouse development and in colorectal tumors. Proc Natl Acad Sci U S A. 2003; 100(6):3299-3304.
21. van den Hoogen C, van der Horst G, Cheung H, Buijs JT, Pelger RC and van der Pluijm G. Integrin alphav expression is required for the acquisition of a metastatic stem/progenitor cell phenotype in human prostate cancer. Am J Pathol. 2011; 179(5):2559-2568.
22. Sottnik JL, Daignault-Newton S, Zhang X, Morrissey C, Hussain MH, Keller ET and Hall CL. Integrin alpha2beta 1 (alpha 2beta 1) promotes prostate cancer skeletal metastasis. Clin Exp Metastasis. 2013; 30(5):569-578.
23. Sun A, Shanmugam I, Song J, Terranova PF, Thrasher JB and Li B. Lithium suppresses cell proliferation by interrupting E2F-DNA interaction and subsequently reducing S-phase gene expression in prostate cancer. Prostate. 2007; 67(9):976-988.
24. Case LB and Waterman CM. Adhesive F-actin waves: a novel integrin-mediated adhesion complex coupled to ventral actin polymerization. PLoS One. 2011; 6(11):e26631.
25. Yu CH, Law JB, Suryana M, Low HY and Sheetz MP. Early integrin binding to Arg-Gly-Asp peptide activates actin polymerization and contractile movement that stimulates outward translocation. Proc Natl Acad Sci U S A. 2011; 108(51):20585-20590.
26. Korur S, Huber RM, Sivasankaran B, Petrich M, Morin P, Jr., Hemmings BA, Merlo A and Lino MM. GSK3beta regulates differentiation and growth arrest in glioblastoma. PLoS One. 2009; 4(10):e7443.
27. Fotovati A, Abu-Ali S, Wang PS, Deleyrolle LP, Lee C, Triscott J, Chen JY, Franciosi S, Nakamura Y, Sugita Y, Uchiumi T, Kuwano M, Leavitt BR, Singh SK, Jury A, Jones C, et al. YB-1 bridges neural stem cells and brain tumor-initiating cells via its roles in differentiation and cell growth. Cancer research. 2011; 71(16):5569-5578.
28. Zhu Q, Yang J, Han S, Liu J, Holzbeierlein J, Thrasher JB and Li B. Suppression of glycogen synthase kinase 3 activity reduces tumor growth of prostate cancer in vivo. Prostate. 2011; 71(8):835-845.
29. Mai W, Kawakami K, Shakoori A, Kyo S, Miyashita K, Yokoi K, Jin M, Shimasaki T, Motoo Y and Minamoto T. Deregulated GSK3{beta} sustains gastrointestinal cancer cells survival by modulating human telomerase reverse transcriptase and telomerase. Clinical cancer research: an official journal of the American Association for Cancer Research. 2009; 15(22):6810-6819.
30. Mazor M, Kawano Y, Zhu H, Waxman J and Kypta RM. Inhibition of glycogen synthase kinase-3 represses androgen receptor activity and prostate cancer cell growth. Oncogene. 2004; 23(47):7882-7892.
31. Schutz SV, Schrader AJ, Zengerling F, Genze F, Cronauer MV and Schrader M. Inhibition of glycogen synthase kinase-3beta counteracts ligand-independent activity of the androgen receptor in castration resistant prostate cancer. PLoS One. 2011; 6(9):e25341.
32. Maitland NJ, Frame FM, Polson ES, Lewis JL and Collins AT. Prostate cancer stem cells: do they have a basal or luminal phenotype? Horm Cancer. 2011; 2(1):47-61.
33. Schwaninger R, Rentsch CA, Wetterwald A, van der Horst G, van Bezooijen RL, van der Pluijm G, Lowik CW, Ackermann K, Pyerin W, Hamdy FC, Thalmann GN and Cecchini MG. Lack of noggin expression by cancer cells is a determinant of the osteoblast response in bone metastases. Am J Pathol. 2007; 170(1):160-175.
34. Zenzmaier C, Heitz M, Klocker H, Buck M, Gardiner RA and Berger P. Elevated levels of Dickkopf-related protein 3 in seminal plasma of prostate cancer patients. J Transl Med. 2011; 9:193.
35. Thudi NK, Martin CK, Murahari S, Shu ST, Lanigan LG, Werbeck JL, Keller ET, McCauley LK, Pinzone JJ and Rosol TJ. Dickkopf-1 (DKK-1) stimulated prostate cancer growth and metastasis and inhibited bone formation in osteoblastic bone metastases. Prostate. 2011; 71(6):615-625.
36. Bisson I and Prowse DM. WNT signaling regulates self-renewal and differentiation of prostate cancer cells with stem cell characteristics. Cell Res. 2009; 19(6):683-697.
37. Yee DS, Tang Y, Li X, Liu Z, Guo Y, Ghaffar S, McQueen P, Atreya D, Xie J, Simoneau AR, Hoang BH and Zi X. The Wnt inhibitory factor 1 restoration in prostate cancer cells was associated with reduced tumor growth, decreased capacity of cell migration and invasion and a reversal of epithelial to mesenchymal transition. Mol Cancer. 2010; 9:162.
38. Lin C, Lu W, Zhai L, Bethea T, Berry K, Qu Z, Waud WR and Li Y. Mesd is a general inhibitor of different Wnt ligands in Wnt/LRP signaling and inhibits PC-3 tumor growth in vivo. FEBS Lett. 2011; 585(19):3120-3125.
39. Thamilselvan V, Menon M and Thamilselvan S. Anticancer efficacy of deguelin in human prostate cancer cells targeting glycogen synthase kinase-3 beta/beta-catenin pathway. Int J Cancer. 2011; 129(12):2916-2927.
40. Majid S, Saini S and Dahiya R. Wnt signaling pathways in urological cancers: past decades and still growing. Mol Cancer. 2012; 11:7.
41. Trowbridge JJ, Xenocostas A, Moon RT and Bhatia M. Glycogen synthase kinase-3 is an in vivo regulator of hematopoietic stem cell repopulation. Nat Med. 2006; 12(1):89-98.
42. Sato N, Meijer L, Skaltsounis L, Greengard P and Brivanlou AH. Maintenance of pluripotency in human and mouse embryonic stem cells through activation of Wnt signaling by a pharmacological GSK-3-specific inhibitor. Nat Med. 2004; 10(1):55-63.
43. Fung TK, Gandillet A and So CW. Selective treatment of mixed-lineage leukemia leukemic stem cells through targeting glycogen synthase kinase 3 and the canonical Wnt/beta-catenin pathway. Curr Opin Hematol. 2012; 19(4):280-286.
44. Kobayashi T, Hino S, Oue N, Asahara T, Zollo M, Yasui W and Kikuchi A. Glycogen synthase kinase 3 and h-prune regulate cell migration by modulating focal adhesions. Mol Cell Biol. 2006; 26(3):898-911.
45. Lapid K, Itkin T, D'Uva G, Ovadya Y, Ludin A, Caglio G, Kalinkovich A, Golan K, Porat Z, Zollo M and Lapidot T. GSK3beta regulates physiological migration of stem/progenitor cells via cytoskeletal rearrangement. J Clin Invest. 2013; 123(4):1705-1717.
46. Marthick JR and Dickinson JL. Emerging putative biomarkers: the role of alpha 2 and 6 integrins in susceptibility, treatment, and prognosis. Prostate Cancer. 2012; 2012:298732.
47. Lipscomb EA and Mercurio AM. Mobilization and activation of a signaling competent alpha6beta4integrin underlies its contribution to carcinoma progression. Cancer Metastasis Rev. 2005; 24(3):413-423.
48. Colombel M, Eaton CL, Hamdy F, Ricci E, van der Pluijm G, Cecchini M, Mege-Lechevallier F, Clezardin P and Thalmann G. Increased expression of putative cancer stem cell markers in primary prostate cancer is associated with progression of bone metastases. Prostate. 2012; 72(7):713-720.
49. van der Horst G, van den Hoogen C, Buijs JT, Cheung H, Bloys H, Pelger RC, Lorenzon G, Heckmann B, Feyen J, Pujuguet P, Blanque R, Clement-Lacroix P and van der Pluijm G. Targeting of alpha(v)-integrins in stem/progenitor cells and supportive microenvironment impairs bone metastasis in human prostate cancer. Neoplasia. 2011; 13(6):516-525.
50. Eaton CL, Colombel M, van der Pluijm G, Cecchini M, Wetterwald A, Lippitt J, Rehman I, Hamdy F and Thalman G. Evaluation of the frequency of putative prostate cancer stem cells in primary and metastatic prostate cancer. Prostate. 2010; 70(8):875-882.